Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:23 10/07/2025 BST			5-day change	1st Jan Change
114.45 ^EUR	+2.83%		+1.55%	-18.19%

07-09	Merck KGAA and preparations for the post-Keytruda era
07-07	European share rise on tech, banks boost with focus on US trade negotiations	RE

MERCK KGAA : Bernstein remains Neutral

Published on 27/05/2025 at 10:34

Florent Cespedes from Bernstein retains his Neutral opinion on the stock. The target price is reduced from EUR 168 to EUR 147.

Latest news about Merck KGaA

Merck KGAA and preparations for the post-Keytruda era	07-09
European share rise on tech, banks boost with focus on US trade negotiations	07-07	RE
Frankfurt Stocks Close: DAX Defies US Tariff Threats Ahead of Deadline	07-07	DP
Stifel Downgrades Merck KGaA to Sell, Cuts PT	07-07	MT
MERCK KGAA : bottom of the DAX, with Stifel downgrade	07-07	CF
Frankfurt stock market opening: DAX rises slightly - US tariffs in focus	07-07	DP
Merck KGaA Shares Approach Yearly Low After Sell Recommendation	07-07	DP
Merck KGaA completed the acquisition of SpringWorks Therapeutics, Inc. from FMR LLC, The Vanguard Group, Inc. and BlackRock, Inc. and others.	07-01	CI
Merck Seals Largest Pharma Deal in Decades	07-01	DP
Germany's Merck KGaA Closes $3.4 Billion Purchase of US-based SpringWorks	07-01	MT
Merck completes acquisition of Springworks – explores further acquisitions	07-01	DP
MERCK KGAA : UBS reiterates its Buy rating	07-01	ZD
Merck: EMD Serono Presents Results On Efficacy And Safety Of Enpatoran	06-12	RE
China's Center for Drug Evaluation Accepts Merck KGaA's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor	06-10	CI
Merck: FDA approves Enflonsia RSV vaccine	06-10	CF
Merck KGaA's Application to Market Tumor Treatment Pimicotinib to Be Reviewed By China	06-10	DJ
Merck KGaA Wins Chinese Approval for Tenosynovial Giant Cell Tumor Treatment	06-10	MT
China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib	06-10	RE
Health insurers in favor of cost containment for drug spending	06-03	DP
MERCK KGAA : JP Morgan reiterates its Buy rating	06-03	ZD
MERCK KGAA : Deutsche Bank maintains a Buy rating	05-30	ZD
Merck KGaA Says Cell Tumor Inhibitor Shows Promise in Late-Stage Trial	05-28	DJ
Bernstein lowers target for Merck KGaA - 'Market Perform'	05-27	DP
MERCK KGAA : Bernstein remains Neutral	05-27	ZD
Equita Keeps Merck KGaA at Buy, Lowers PT	05-26	MT

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (42.1%); - pharmaceutical products (40%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.9%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.7%), Switzerland (1.9%), Europe (22.6%), the United States (25.7%), North America (1.3%), China (13.5%), Asia/Pacific (19.6%), Latin America (7%), Middle East and Africa (3.7%).

Employees

62,604

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Call

More about the company